Everything You Need to Know About Blood Sugar Tests

Everything You Need to Know About Blood Sugar TestsByRachael Zimlich, BSN, RNPublished on January 10, 2022Medically reviewed byDo-Eun Lee, MDDiabetes is a chronic condition tha

Updated on: March 17,2024 0

Everything You Need to Know About Blood Sugar Tests

Everything You Need to Know About Blood Sugar TestsByRachael Zimlich, BSN, RNPublished on January 10, 2022Medically reviewed byDo-Eun Lee, MDDiabetes is a chronic condition tha

Updated on:March 17,2024 0

Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma

October 22, 2018Onclive TeamLong-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treate

Updated on: October 24,2023 270

Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma

October 22, 2018Onclive TeamLong-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treate

Updated on:October 24,2023 270

Blood Thinners: What You Should Know

Blood Thinners: What You Should KnowByAngela Ryan Lee, MDPublished on January 24, 2022Medically reviewed byAnisha Shah, MDBlood thinners are medications used to treat and

Updated on: March 17,2024 0

Blood Thinners: What You Should Know

Blood Thinners: What You Should KnowByAngela Ryan Lee, MDPublished on January 24, 2022Medically reviewed byAnisha Shah, MDBlood thinners are medications used to treat and

Updated on:March 17,2024 0

Progression-free survival increased with zanubrutinib in leukemia

by Elana Gotkine HealthDay ReporterProgression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or s

Updated on: December 19,2023 12

Progression-free survival increased with zanubrutinib in leukemia

by Elana Gotkine HealthDay ReporterProgression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or s

Updated on:December 19,2023 12

Interrupting endocrine therapy to pursue pregnancy doesn't lead to worse short-term breast cancer recurrence rates

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainBreast cancer patients who paused their endocrine therapy to try to get pregnant experienced short-term rates of breas

Updated on: January 08,2024 10

Interrupting endocrine therapy to pursue pregnancy doesn't lead to worse short-term breast cancer recurrence rates

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainBreast cancer patients who paused their endocrine therapy to try to get pregnant experienced short-term rates of breas

Updated on:January 08,2024 10

Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations

byUniversity of Texas M. D. Anderson Cancer CenterBone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: WikipediaResearchers from The University of Texas MD

Updated on: December 19,2023 12

Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations

byUniversity of Texas M. D. Anderson Cancer CenterBone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: WikipediaResearchers from The University of Texas MD

Updated on:December 19,2023 12

Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on: December 20,2023 11

Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on:December 20,2023 11

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on: December 22,2023 13

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on:December 22,2023 13

Mechanics of breast cancer metastasis discovered, offering target for treatment

Mechanics of breast cancer metastasis discovered, offering target for treatmentby Adrienne Berard,Pennsylvania State UniversityA human breast cancer cell, adenocarcinoma MDA-MB-231, demonstrates

Updated on: October 30,2023 12

Mechanics of breast cancer metastasis discovered, offering target for treatment

Mechanics of breast cancer metastasis discovered, offering target for treatmentby Adrienne Berard,Pennsylvania State UniversityA human breast cancer cell, adenocarcinoma MDA-MB-231, demonstrates

Updated on:October 30,2023 12

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r

Updated on: October 15,2023 27

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r

Updated on:October 15,2023 27

Why don't T cells destroy solid tumors during immunotherapy?

byUniversity of North Carolina Health Care3-D image of a T cell experiencing cell stress: endoplasmic reticulum (green), mitochondria (purple). Credit: Elizabeth Hunt, UNC School of MedicineThe

Updated on: January 08,2024 10

Why don't T cells destroy solid tumors during immunotherapy?

byUniversity of North Carolina Health Care3-D image of a T cell experiencing cell stress: endoplasmic reticulum (green), mitochondria (purple). Credit: Elizabeth Hunt, UNC School of MedicineThe

Updated on:January 08,2024 10

New epigenetic markers for prostate cancer discovered

byGarvan Institute of Medical ResearchHistopathological image of a high grade prostate cancer. Credit: Prof James KenchNew epigenetic biomarkers to predict more aggressive forms of prostate canc

Updated on: December 21,2023 10

New epigenetic markers for prostate cancer discovered

byGarvan Institute of Medical ResearchHistopathological image of a high grade prostate cancer. Credit: Prof James KenchNew epigenetic biomarkers to predict more aggressive forms of prostate canc

Updated on:December 21,2023 10